ClinicalTrials.gg

Program

florbetaben f-18

Also written as “Florbetaben (BAY94-9172)”, “[18F]florbetaben” and “Florbetaben F18”.

Its studies are mostly in Alzheimer Disease · Amyloid Neuropathies, Familial · Down Syndrome, led by 2 companies.

Furthest: phase 4, since Feb 4, 20168 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheus70 open or runningphase 4since Feb 4, 2016Sep 9, 2008none ahead
Sinotau Pharmaceutical Group10 open or runningno phasesince Aug 8, 2022Aug 8, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2008First study: phase 2 study in Alzheimer DiseaseNew to LantheusLantheus · NCT00750282 · 422 enrolled · United States, Australia, Germany and more
  2. Jun 24, 2009Phase 2 study in Down SyndromeLantheus · NCT00928304 · 109 enrolled · United States
  3. Nov 16, 2009Phase 3 study in Alzheimer DiseaseLantheus · NCT01020838 · 218 enrolled · United States, Australia, France and more
  4. Apr 1, 2010Phase 1 study in Alzheimer DiseaseLantheus · NCT01138111 · 45 enrolled · Australia
  5. Feb 4, 2016Phase 4 study in Alzheimer DiseaseLantheus · NCT02681172 · 218 enrolled · France
  6. Jan 6, 2022Phase 3 study in Amyloid Neuropathies, FamilialLantheus · NCT05184088 · 244 enrolled · United States, Germany, Spain and more
  7. Aug 8, 2022Sinotau Pharmaceutical Group’s first study: no phase study in Alzheimer DiseaseNew to Sinotau Pharmaceutical GroupSinotau Pharmaceutical Group · NCT05527288 · 50 enrolled · China
  8. Dec 19, 2024Phase 1 study in Amyloid Neuropathies, FamilialLantheus · NCT06790394 · 15 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06790394Amyloid Neuropathies, Familial · United Kingdom1CompletedLantheusOct 7, 202615
NCT05527288Alzheimer Disease · China–CompletedSinotau Pharmaceutical GroupSep 12, 202150
NCT05184088Amyloid Neuropathies, Familial · United States, Germany, Spain and more3CompletedLantheusApr 21, 2026244
NCT02681172Alzheimer Disease · France4CompletedLantheusSep 2016218
NCT01138111Alzheimer Disease · Australia1CompletedLantheusDec 201145
NCT01020838Alzheimer Disease · United States, Australia, France and more3CompletedLantheusSep 2011218
NCT00928304Down Syndrome · United States2CompletedLantheusJan 2011109
NCT00750282Alzheimer Disease · United States, Australia, Germany and more2CompletedLantheusNov 2010422

How it is read

Names in the registry

  • “Florbetaben (BAY94-9172)”, 4 entries
  • “[18F]florbetaben”, 1 entry
  • “Florbetaben F18”, 1 entry
  • “Neuraceq (florbetaben 18F)”, 1 entry
  • “Drug: [18F]florbetaben”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
florbetaben f-18 (Lantheus): development program | ClinicalTrials.gg